The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00336115

Enrollment

Registered

2006-06-12

Start date

2006-07-31

Completion date

2008-05-31

Last updated

2007-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pertussis

Keywords

pertussis, bone marrow transplant

Brief summary

The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.

Interventions

BIOLOGICALTetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

* Aged 18-64 * BMT at the QEII Health Sciences Centre * BMT within last 12 months * Able to read and write English language * Able to give consent

Exclusion criteria

* Active infection * Active GVHD * Recent IVIG * Allergy to components of vaccine * Diphtheria or tetanus vaccination within 18 months

Design outcomes

Primary

Measure	Time frame
Safety of the vaccine	28 days post-dose

Secondary

Measure	Time frame
Immunogenicity of vaccine	60 days post-dose

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026